News Conference News ACC 2024 KARDIA-2: Zilebesiran Drops BP on Top of Common Antihypertensives Shelley Wood April 11, 2024
News Conference News ACC 2022 New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More Shelley Wood April 01, 2022
News Conference News ACC 2021 Dapagliflozin No Help, but No Harm, in Hospitalized COVID-19 Patients Shelley Wood May 16, 2021
News Conference News ACC 2020 ISCHEMIA in Print: New MI Data and More Calls for Longer Follow-up Shelley Wood March 30, 2020
News Conference News ACC 2018 Low-Dose, Three-Drug Polypill TRIUMPHs for Blood Pressure Shelley Wood March 12, 2018
News Conference News ACC 2018 ACC 2018, Day Three: Gout, Hypertension, Diabetes, PFO Closure, DAPT, NOAC Reversal, and More Shelley Wood March 12, 2018
News Conference News ACC 2018 ACC 2018, Day Two: Antiplatelets in ACS, Dabigatran in Noncardiac Surgery, and More Shelley Wood March 11, 2018
News Conference News ACC 2018 ACC 2018, Day One: Live From Orlando! The ODYSSEY Begins Shelley Wood March 10, 2018
News Conference News ACC 2018 ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last Shelley Wood March 05, 2018
News Conference News ACC 2017 ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More Shelley Wood March 10, 2017
News Conference News ACC 2017 Does Hormone Replacement Therapy Curb Atherosclerosis? New Imaging Study Opens Old Questions Shelley Wood March 09, 2017